WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance

• DOI: 10.4149/neo_2009_05_393
• Publication Date: 2009-07-04T15:05:22Z
• Authors: E. OTAHALOVA; V. ULLMANNOVA-BENSON; H. KLAMOVA; C. HASKOVEC
• Keywords: breakpoint cluster region; Imatinib Mesylate; ABL; Chronic myelogenous leukemia

The determination of patient's resistance to a particular drug contributes more efficient therapeutical approach. aim this study was evaluate if the responsiveness Chronic Myeloid Leukemia (CML) patients Imatinib therapy predictable from WT1 gene expression in peripheral blood leukocytes. To examine we implemented an vitro cultivation primary cells 48 CML with Imatinib. effect characterized not only by but also BCR-ABL, and proliferative factor Ki-67. <br />Our results showed that leukocytes patients, clinically responsive treatment, significantly decreased after incubation It accompanied inhibition Ki-67 BCR-ABL. In resistant Imatinib, WT1, Ki-67, BCR-ABL remained unaffected. presented testing using enabled clinicians predict